Medtronic plc (MDT) Financial Statements
Historical financial data — 43 statements covering FY2016–FY2025
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter h...
Medtronic plc's revenue increased 3.6% year over year, from $32.36B to $33.54B.
Net income increased 26.8% over the same period, from $3.68B to $4.66B.
Over the 9-year period from FY2016 to FY2025, revenue grew by 16% in total.
Total debt increased by 14.0% to $28.52B.
The debt-to-equity ratio stands at 0.59, indicating a moderate leverage profile.
Operating cash flow grew 3.8% to $7.04B.
Medtronic plc maintains a healthy net profit margin of 13.9%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2024 | $15.69B+103.7% | $1.70B | $10.30B | $2.61B | $1.54B | $90.09B | $25.08B | $51.46B |
| Q3 FY2024 | $23.77B+51.6% | $3.02B | $15.60B | $4.09B | $4.01B | $90.84B | $25.18B | $51.79B |
| Q1 FY2025 | $7.92B-66.7% | $1.04B | $5.15B | $1.28B | $986.0M | $89.75B | $27.86B | $47.95B |
| Q2 FY2025 | $16.32B+106.2% | $2.31B | $10.61B | $2.87B | $1.94B | $90.04B | $28.33B | $48.49B |
| Q3 FY2025 | $24.61B+50.8% | $3.61B | $16.13B | $4.52B | $4.52B | $89.97B | $26.61B | $49.39B |
| Q1 FY2026 | $8.58B-65.1% | $1.04B | $5.58B | $1.45B | $1.09B | $90.97B | $28.61B | $47.89B |
| Q2 FY2026 | $17.54B+104.5% | $2.41B | $11.48B | $3.13B | $2.01B | $91.35B | $29.10B | $48.65B |
| Q3 FY2026 | $26.56B+51.4% | $3.56B | $17.23B | $4.59B | $4.76B | $91.48B | $28.07B | $48.98B |
Balance Sheet Summary (Latest Period)
Total Assets
$91.68B
Total Liabilities
$43.42B
Total Equity
$48.02B
Cash & Equivalents
$8.96B
Total Debt
$28.52B
Current Assets
$23.81B
Current Liabilities
$12.88B
Retained Earnings
$31.48B